Skip to main content
  • Original article
  • Open access
  • Published:

Assessment of high-dose inhalational corticosteroids vs systemic corticosteroids in acute exacerbations of COPD in diabetic patients

Abstract

Background

Systemic corticosteroids (SCS) are effective in the management of acute exacerbation of chronic obstructive pulmonary disease (AECOPD). However, they are not without adverse effects, especially hyperglycemia. Inhaled corticosteroids (ICS) showed satisfactory outcomes with good safety. These benefits were not evaluated in patients with AECOPD with diabetes mellitus. The aim was to compare the efficacy and safety of high dose of ICS vs SCS in the treatment of AECOPD in diabetic patients.

Patients and methods

A total of 126 patients with AECOPD were screened, and thirty of them were found to be eligible and were enrolled into two groups: group 1 (n=15) received 1mg budesonide by jet nebulizer four times daily, and group 2 (n=15) received 40mg prednisolone or equivalent systemically. Postbronchodilator forced expiratory volume in 1 s (FEV1%) of predicted was measured at day 1 and day 7, and random blood sugar (RBG) was measured twice daily in all patients.

Results

There was a significant increase in the mean FEV1 at day 7 as compared with mean FEV1 at day 1 in groups 1 and 2, with the increase in mean FEV1 being 19.6 and 21% in groups 1 and 2, respectively. There was a significant difference, with higher mean RBG in group 2 when compared with group 1, at day 4 of treatment and continued onward. Interestingly, there was a significant elevation in mean RBG among patients in group 2 (SCS) starting by day 3 of treatment and continued onward, with no significant rise in the first two days, although there was no evident effect of ICS on the mean RBG among patients in group 1 (ICS) during the follow-up days.

Conclusion

Both ICS and SCS improve airflow in patients with AECOPD, taking into consideration the existence of diabetes mellitus. ICS may be an excellent substitute to SCS in the treatment of AECOPD in diabetic patients.

References

  1. World Health Organization. Chronic obstructive pulmonary disease (COPD): burden of COPD. http://www.who.int/respiratory/copd/burden/en/ (accessed March 13, 2014).

  2. Rana JS, Mittleman MA, Sheikh J, Hu FB, Manson JE, Colditz GA, et al. Chronic obstructive pulmonary disease, asthma, and risk of type 2 diabetes in women. Diabetes Care 2004; 27:2478–2484.

    Article  Google Scholar 

  3. Mirrakhimov AE. Chronic obstructive pulmonary disease and glucose metabolism: a bitter sweet symphony. Cardiovasc Diabetol 2012; 11:132.

    Article  Google Scholar 

  4. Celli BR, MacNee W. ATS/ERS Task Force, Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932–946.

    Article  CAS  Google Scholar 

  5. The NHMRC and the Diabetes Australia Guideline Development Consortium. National evidence based guidelines for the management of type 2 diabetes mellitus; 2005. Available at: http://www.nhmrc.gov.au/publications/synopses/di7todi13syn.htm. [Accessed on Jan 2005].

  6. Caughey GE, Roughead EE, Vitry AI, McDermott RA, Shakib S, Gilbert AL. Comorbidity in the elderly with diabetes: identification of areas of potential treatment conflicts. Diabetes Res Clin Prac 2010; 87:385–393.

    Article  Google Scholar 

  7. Belda J, Margarit G, Martinez C, Bellido-Casado J, Casan P, Torrejón M, et al. Anti-inflammatory effects of high-dose inhaled fluticasone versus oral prednisone in asthma exacerbations. Eur Respir J 2007; 30:1143–1149.

    Article  CAS  Google Scholar 

  8. Allen DB, Bielory L, Derendorf H, Dluhy R, Colice GL, Szefler SJ. Inhaled corticosteroids: past lessons and future issues. J Allergy Clin Immunol 2003; 112 (3 Suppl): S1–S40.

    Article  CAS  Google Scholar 

  9. Pedersen S, O’Byrne PM. A comparison of the efficacy and safety of inhaled corticosteroids in asthma. Allergy 1997; 52 (Suppl 39):1–34.

    Article  CAS  Google Scholar 

  10. O’Byrne PM, Rennard S, Gerstein H, Radner F, Peterson S, Lindberg B, et al. Risk of new onset diabetes mellitus in patients with asthma or COPD taking inhaled corticosteroids. Respir Med 2012; 106:1487–1493.

    Article  Google Scholar 

  11. Reynolds RM, Labad J, Sears AV, Williamson RM, Strachan MW, Deary IJ, et al. Edinburgh type 2 diabetes study investigators: glucocorticoid treatment and impaired mood, memory and metabolism in people with diabetes: the Edinburgh type 2 diabetes study. Eur J Endocrinol 2012; 166:861–868.

    Article  CAS  Google Scholar 

  12. Global Initiative for Obstructive Lung Disease – Updated 2014. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Available at: http://www.goldcopd.org. [Accessed on Feb 2014].

  13. American Diabetes Association 2015 guidelines. Available at: http://www.ndei.org/ADA-diabetes-management-guidelines-diagnosis-A1C-testing.aspx. [Accessed on Jan 2015].

  14. Feary JR, Rodrigues LC, Smith CJ, Hubbard RB, Gibson JE. Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. Thorax 2010; 65:956–962.

    Article  Google Scholar 

  15. Maltais F, Ostinelli J, Bourbeau J, Tonnel AB, Jacquemet N, Haddon J, et al. Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med 2002; 165:698–703.

    Article  Google Scholar 

  16. Gunen H, Hacievliyagil SS, Yetkin O, Gulbas G, Mutlu LC, In E. The role of nebulised budesonide in the treatment of exacerbations of COPD. Eur Respir J 2007; 29:660–667.

    Article  CAS  Google Scholar 

  17. Ding Z, Li X, Lu Y, Rong G, Yang R, Zhang R, et al. A randomized, controlled multicentric study of inhaled budesonide and intravenous methylprednisolone in the treatment on acute exacerbation of chronic obstructive pulmonary disease. Respir Med 2016; 121:39e47.

    Article  Google Scholar 

  18. Morice AH, Morris D, Matthew PL. Comparison of nebulized budesonide with oral prednisolone in the treatment of exacerbations of obstructive pulmonary disease. Pharmacol Ther 1996; 60:675–678.

    Article  CAS  Google Scholar 

  19. Sun X, He Z, Zhang J, Deng J, Bai J, Li M, et al. Compare the efficacy of inhaled budesonide and systemic methylprednisolone on systemic inflammation of AECOPD. Pulmon Pharmacol Ther 2015; 31:111e116.

    Article  Google Scholar 

  20. Verma VK, Nim RK, Kumar M, Singh P, Singh G, Singh AK. Assessment of glycemic status of COPD patients on long term corticosteroid therapy. Int J Res Med Sci 2017; 5:3997–4002.

    Article  Google Scholar 

  21. Samy S, Abbas K, Pierre E. Inhaled corticosteroids and the risks of diabetes onset and progression. Am J Med 2010; 123:1001–1006.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Haytham S. Diab MD.

Additional information

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Magdy, A.S., Diab, H.S. Assessment of high-dose inhalational corticosteroids vs systemic corticosteroids in acute exacerbations of COPD in diabetic patients. Egypt J Bronchol 13, 610–615 (2019). https://doi.org/10.4103/ejb.ejb_71_19

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.4103/ejb.ejb_71_19

Keywords